{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:14:11Z","timestamp":1793996051024,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01584-y","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:48:51Z","timestamp":1762606131000},"page":"377-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargav","family":"Lakshminarasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Alam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichiren","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bregt","family":"Kappelhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Weatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"2","key":"1584_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jdv.18720","volume":"37","author":"JC Prinz","year":"2023","unstructured":"Prinz JC, Choon SE, Griffiths CEM, Merola JF, Morita A, Ashcroft DM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):256\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"1584_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","volume":"23","author":"S Marrakchi","year":"2022","unstructured":"Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1584_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jaad.2023.09.080","volume":"90","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Elston CA, Elewski BE, Ferris LK, Gottlieb AB, Lebwohl MG. Generalized pustular psoriasis: a consensus statement from the national psoriasis foundation. J Am Acad Dermatol. 2024;90(4):727\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1584_CR4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370.","journal-title":"J Dermatol"},{"issue":"4","key":"1584_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.18851","volume":"37","author":"L Puig","year":"2023","unstructured":"Puig L, Choon SE, Gottlieb AB, Marrakchi S, Prinz JC, Romiti R, et al. Generalized pustular psoriasis: a global delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023;37(4):737\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1584_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","volume":"11","author":"B Strober","year":"2021","unstructured":"Strober B, Kotowsky N, Medeiros R, Mackey RH, Harrold LR, Valdecantos WC, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1584_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13555-024-01103-5","volume":"14","author":"T Bhutani","year":"2024","unstructured":"Bhutani T, Farberg AS. Clinical and disease burden of patients with generalized pustular psoriasis: a review of real-world evidence. Dermatol Ther (Heidelb). 2024;14(2):341\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 1","key":"1584_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40257-021-00663-y","volume":"23","author":"DV Reisner","year":"2022","unstructured":"Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(Suppl 1):65\u201371.","journal-title":"Am J Clin Dermatol"},{"key":"1584_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/24755303251318976","volume":"10","author":"B Elewski","year":"2025","unstructured":"Elewski B, Lebwohl MG. Management of chronic generalized pustular psoriasis: a review and expert opinion. J Psoriasis Psoriatic Arthritis. 2025;10:58\u201366.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"10","key":"1584_CR10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","volume":"18","author":"H Bachelez","year":"2022","unstructured":"Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033\u201347.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1584_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-023-01073-0","volume":"14","author":"A Balato","year":"2024","unstructured":"Balato A, Ambrogio F, Burlando M, Carrera CG, Chiricozzi A, Esposito M, et al. Commentary: unmet needs in generalized pustular psoriasis in clinical practice. Dermatol Ther (Heidelb). 2024;14(1):5\u201313.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1584_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2133.1969.tb15995.x","volume":"81","author":"TJ Ryan","year":"1969","unstructured":"Ryan TJ, Baker H. Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis. Evaluation and prognosis based on the study of 104 cases. Br J Dermatol. 1969;81(2):134\u201345.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1584_CR13","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/exd.14765","volume":"32","author":"N Kodali","year":"2023","unstructured":"Kodali N, Blanchard I, Kunamneni S, Lebwohl MG. Current management of generalized pustular psoriasis. Exp Dermatol. 2023;32(8):1204\u201318.","journal-title":"Exp Dermatol"},{"issue":"6","key":"1584_CR14","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaad.2021.06.008","volume":"86","author":"H Miyachi","year":"2022","unstructured":"Miyachi H, Konishi T, Kumazawa R, Matsui H, Shimizu S, Fushimi K, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1584_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaad.2023.04.066","volume":"89","author":"O Ericson","year":"2023","unstructured":"Ericson O, L\u00f6fvendahl S, Norlin JM, Gyllensv\u00e4rd H, Schmitt-Egenolf M. Mortality in generalized pustular psoriasis: a population-based national register study. J Am Acad Dermatol. 2023;89(3):616\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1584_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/bjd\/ljad384","volume":"190","author":"JH Haugaard","year":"2023","unstructured":"Haugaard JH, Thein D, Egeberg A. Characteristics and prognosis of first-time hospitalized patients with generalized pustular psoriasis: insights from national databases. Br J Dermatol. 2023;190(1):131\u20132.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1584_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1584_CR18","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaad.2018.12.037","volume":"80","author":"A Dhana","year":"2019","unstructured":"Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1332\u201343.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1584_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jid.2023.11.004","volume":"144","author":"F Ahmad","year":"2024","unstructured":"Ahmad F, Alam MA, Ansari AW, Jochebeth A, Leo R, Al-Abdulla MN, et al. Emerging role of the IL-36\/IL-36R axis in multiple inflammatory skin diseases. J Invest Dermatol. 2024;144(2):206\u201324.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1584_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41569-024-01097-9","volume":"22","author":"JM Gelfand","year":"2025","unstructured":"Gelfand JM, Song WB, Langan SM, Garshick MS. Cardiodermatology: the heart of the connection between the skin and cardiovascular disease. Nat Rev Cardiol. 2025;22(5):354\u201371.","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"1584_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","volume":"143","author":"JM Gelfand","year":"2007","unstructured":"Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493\u20139.","journal-title":"Arch Dermatol"},{"key":"1584_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/24755303251344155","author":"AB Gottlieb","year":"2025","unstructured":"Gottlieb AB, Crooke Kwiatkowski H, Semeco J, Lakshminarasimhan B, Strober B, Lebwohl M. All-cause mortality is higher in generalized pustular psoriasis (GPP) than plaque psoriasis and the general population: a US-based claims analysis. J Psoriasis Psoriatic Arthritis. 2025. https:\/\/doi.org\/10.1177\/24755303251344155.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"1584_CR23","first-page":"1","volume":"2","author":"J Peterson","year":"2011","unstructured":"Peterson J, Welch V, Losos M, Tugwell P. The newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hosp Res Inst. 2011;2(1):1\u201312.","journal-title":"Ottawa: Ottawa Hosp Res Inst"},{"key":"1584_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/9781119536604.ch10","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JJ Deeks","year":"2019","unstructured":"Deeks JJ, Higgins JP, Altman DG, Group obotCSM. Chapter 10: analysing data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions. Wiley; 2019. p. 241\u201384."},{"issue":"5","key":"1584_CR25","first-page":"589","volume":"23","author":"M Schultze","year":"2025","unstructured":"Schultze M, Kossack N, Kromer C, Zimmermann TM, Kolb N. Epidemiology of generalized pustular psoriasis in Germany: analyzing factors influencing prevalence estimates health insurance data. JDDG: J Der Deutschen Dermatol Gesellschaft. 2025;23(5):589\u201397.","journal-title":"JDDG: J Der Deutschen Dermatol Gesellschaft"},{"issue":"6","key":"1584_CR26","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/jdv.19901","volume":"38","author":"M Viguier","year":"2024","unstructured":"Viguier M, Bentayeb M, Azzi J, de Pouvourville G, Gloede T, Langellier B, et al. Generalized pustular psoriasis: a nationwide population-based study using the national health data system in France. J Eur Acad Dermatol Venereol. 2024;38(6):1131\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1584_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/bjd\/ljae217","volume":"191","author":"M Frysz","year":"2024","unstructured":"Frysz M, Patel S, Li Marie OY, Griffiths CEM, Warren RB, Ashcroft DM. Prevalence, incidence, mortality and healthcare resource use for generalized pustular psoriasis, palmoplantar pustulosis and plaque psoriasis in England: a population-based cohort study. Br J Dermatol. 2024;191(4):529\u201338.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1584_CR28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155236","volume":"7","author":"J El-Awaisi","year":"2022","unstructured":"El-Awaisi J, Kavanagh DP, Rink MR, Weston CJ, Drury NE, Kalia N. Targeting IL-36 improves age-related coronary microcirculatory dysfunction and attenuates myocardial ischemia\/reperfusion injury in mice. JCI Insight. 2022;7(5):e155236.","journal-title":"JCI Insight"},{"issue":"10","key":"1584_CR29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1159\/000525845","volume":"183","author":"S Kazemian","year":"2022","unstructured":"Kazemian S, Ahmadi R, Rafiei A, Azadegan-Dehkordi F, Khaledifar A, Abdollahpour-Alitappeh M, et al. The serum levels of IL-36 in patients with coronary artery disease and their correlation with the serum levels of IL-32, IL-6, TNF-\u03b1, and oxidative stress. Int Arch Allergy Immunol. 2022;183(10):1137\u201345.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"1584_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14814","volume":"34","author":"C Kromer","year":"2021","unstructured":"Kromer C, Loewe E, Schaarschmidt ML, Pinter A, Gerdes S, Herr R, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34(2):e14814.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1584_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jaad.2025.02.018","volume":"92","author":"JLW Rhoads","year":"2025","unstructured":"Rhoads JLW, Lavasani L, Rasouliyan L, Laouri M, Noe M. Real-world clinical characteristics and treatment patterns of generalized pustular psoriasis flares. J Am Acad Dermatol. 2025;92(6):1243\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1584_CR32","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1007\/s13555-024-01306-w","volume":"14","author":"M Ko\u0142t-Kami\u0144ska","year":"2024","unstructured":"Ko\u0142t-Kami\u0144ska M, Marek-J\u00f3zefowicz L, Krajewski P, Nowowiejska J, Siekierko A, Duchnik E, et al. Characteristics of patients with generalized pustular psoriasis: a report of the polish generalized pustular psoriasis group. Dermatol Ther (Heidelb). 2024;14(12):3379\u201393.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1584_CR33","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/jdv.19808","volume":"38","author":"P Wolf","year":"2024","unstructured":"Wolf P, Ceovic R, Conrad C, Falkensteiner K, Graier T, Ko\u0142t-Kami\u0144ska M, et al. Characteristics and management of generalized pustular psoriasis (GPP): experience from the central and eastern Europe (CEE) GPP expert network. J Eur Acad Dermatol Venereol. 2024;38(8):1531\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1584_CR34","unstructured":"Visvanathan S, Farag A, Morita A, Lebwohl MG, Warren RB, Burden AD, et al. 278 Spesolimab treatment controls GPP disease characteristics in acute and chronic phases. ISDS 2023; Vienna, Austria (2023)."},{"issue":"8","key":"1584_CR35","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.jid.2024.06.1119","volume":"144","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Gudjonsson JE, Morita A, Lebwohl MG, Warren RB, Mostaghimi A, et al. LB946 spesolimab controls chronic inflammation in GPP. J Invest Dermatol. 2024;144(8):S165.","journal-title":"J Invest Dermatol"},{"issue":"26","key":"1584_CR36","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340.","journal-title":"N Engl J Med"},{"key":"1584_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.864185","volume":"9","author":"P Anyfanti","year":"2022","unstructured":"Anyfanti P, Margouta A, Goulas K, Gavriilaki M, Lazaridou E, Patsatsi A, et al. Endothelial dysfunction in psoriasis: an updated review. Front Med Lausanne. 2022;9:864185.","journal-title":"Front Med Lausanne"},{"issue":"5","key":"1584_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/exd.13228","volume":"26","author":"C Bridgewood","year":"2017","unstructured":"Bridgewood C, Stacey M, Alase A, Lagos D, Graham A, Wittmann M. IL-36\u03b3 has proinflammatory effects on human endothelial cells. Exp Dermatol. 2017;26(5):402\u20138.","journal-title":"Exp Dermatol"},{"issue":"11","key":"1584_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116270","volume":"25","author":"R Teshima","year":"2024","unstructured":"Teshima R, Saito-Sasaki N, Sawada Y. Generalized pustular psoriasis and systemic organ dysfunctions. Int J Mol Sci. 2024;25(11):6270.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1584_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4103\/0378-6323.18007","volume":"71","author":"AC Inamadar","year":"2005","unstructured":"Inamadar AC, Palit A. Acute skin failure: concept, causes, consequences and care. Indian J Dermatol Venereol Leprol. 2005;71(6):379\u201385.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"1584_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41392-021-00816-9","volume":"6","author":"YY Zhang","year":"2021","unstructured":"Zhang YY, Ning BT. Signaling pathways and intervention therapies in sepsis. Signal Transduct Target Ther. 2021;6(1):407.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1584_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s13054-023-04777-z","volume":"27","author":"H Wang","year":"2023","unstructured":"Wang H, Wang M, Chen J, Hou H, Guo Z, Yang H, et al. Interleukin-36 is overexpressed in human sepsis and IL-36 receptor deletion aggravates lung injury and mortality through epithelial cells and fibroblasts in experimental murine sepsis. Crit Care. 2023;27(1):490.","journal-title":"Crit Care"},{"issue":"5","key":"1584_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/SHK.0b013e3182a66bd6","volume":"40","author":"RS Samraj","year":"2013","unstructured":"Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock. 2013;40(5):358\u201365.","journal-title":"Shock"},{"issue":"4","key":"1584_CR44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/HCO.0000000000001215","volume":"40","author":"JE Chia","year":"2025","unstructured":"Chia JE, Ang SP. Elevated C-reactive protein and cardiovascular risk. Curr Opin Cardiol. 2025;40(4):237\u201343.","journal-title":"Curr Opin Cardiol"},{"issue":"11","key":"1584_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297","volume":"18","author":"K R\u00f8nholt","year":"2017","unstructured":"R\u00f8nholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1584_CR46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","volume":"84","author":"RG Langley","year":"2021","unstructured":"Langley RG, Poulin Y, Srivastava B, Lafferty KP, Fakharzadeh S, Langholff W, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol. 2021;84(1):60\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1584_CR47","doi-asserted-by":"publisher","first-page":"1359481","DOI":"10.3389\/fimmu.2024.1359481","volume":"15","author":"EC Gwillim","year":"2024","unstructured":"Gwillim EC, Nichols AJ. Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval. Front Immunol. 2024;15:1359481.","journal-title":"Front Immunol"},{"issue":"10412","key":"1584_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","volume":"402","author":"A Morita","year":"2023","unstructured":"Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541\u201351.","journal-title":"Lancet"},{"issue":"3","key":"1584_CR49","doi-asserted-by":"publisher","first-page":"AB316","DOI":"10.1016\/j.jaad.2024.07.1256","volume":"91","author":"AB Gottlieb","year":"2024","unstructured":"Gottlieb AB, Strober B, Kokolakis G, Merola JF, Zheng M, Langley R, et al. 51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per dermatology life quality index scores: data from the Effisayil 2 trial. J Am Acad Dermatol. 2024;91(3):AB316.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1584_CR50","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jid.2024.05.034","volume":"145","author":"A Farag","year":"2025","unstructured":"Farag A, Visvanathan S, Bachelez H, Morita A, Lebwohl MG, Barker JN, et al. Spesolimab reduces inflammation in generalized pustular psoriasis: molecular characterization of flare treatment in EFFISAYIL 1. J Invest Dermatol. 2025;145(3):573-82.e8.","journal-title":"J Invest Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01584-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:03:36Z","timestamp":1770192216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01584-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01584-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bruce Strober reported receiving honoraria as a consultant for AbbVie, Alumis, Almirall, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, CorEvitas, Dermavant, Immunovant, Janssen, Leo, Eli Lilly, Maruho, Neurocrine, Novartis, Okura, Meiji Seika Pharma, Protagonist, Pfizer, UCB Pharma, Rapt, Regeneron, Sanofi-Genzyme, Takeda and Union Therapeutics; stock options from Mindera Health; has participated as a speaker for AbbVie, Arcutis, Eli Lilly, Incyte, Johnson & Johnson Regeneron and Sanofi-Genzyme; consulting fees from CorEvitas Psoriasis Registry (Scientific Co-Director); and a role as an investigator for CorEvitas Psoriasis Registry. Llu\u00eds Puig reported receiving research grants\/support from AbbVie, Almirall, Amgen, LEO Pharma, Lilly, Sun Pharma and UCB; and consultancy or speaker\u2019s honoraria from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius-Kabi, Horizon (DSMB), J&J Innovative Medicine, LEO Pharma, Lilly, Novartis, Pfizer, Samsung-Bioepis, Sandoz, STADA, Sun Pharma, Takeda and UCB. Llu\u00eds Puig is a member of the editorial board of\n                      Dermatology and Therapy\n                      but was not involved in the processing or review of this manuscript by the journal. Mark Lebwohl is an employee of Mount Sinai and reported receiving research funds from AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Mark Lebwohl is a member of the editorial board of\n                      Dermatology and Therapy\n                      but was not involved in the processing or review of this manuscript by the journal. Bhargav Lakshminarasimhan, Shah Alam Khan, Nichiren Pillai, Bregt Kappelhoff and Amy Weatherill are employees of Boehringer Ingelheim. Richard Warren reported receiving research grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, Leo, Novartis, Pfizer and UCB; and consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Galderma, GSK, Immunocore, Janssen, Lilly, Leo, Meiji Pharma, Nektar Therapeutics, Novartis, Pfizer, RAPT Pharmaceuticals, Sanofi, Sun Pharma, Takeda, UCB and UNION. Richard Warren is the Editor-in-Chief of\n                      Dermatology and Therapy\n                      for Europe but was not involved in the processing or review of this manuscript by the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is a meta-analysis of existing data and was therefore not considered for institutional review board review or require informed consent for participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}